

# Drug Policy:

## Inlyta™ (axitinib)

<b>POLICY NUMBER</b> UM ONC_1223	<b>SUBJECT</b> Inlyta™ (axitinib)		<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 of 3</b>
<b>DATES COMMITTEE REVIEWED</b> 10/03/12, 12/11/13, 03/16/15, 05/24/16, 03/06/17, 03/14/18, 03/13/19, 12/11/19, 03/11/20, 01/13/21, 11/15/21, 12/08/21, 05/11/22, 11/09/22, 03/08/23, 05/10/23, 11/08/23, 11/13/24	<b>APPROVAL DATE</b> November 13, 2024	<b>EFFECTIVE DATE</b> November 29, 2024	<b>COMMITTEE APPROVAL DATES</b> 10/03/12, 12/11/13, 03/16/15, 05/24/16, 03/06/17, 03/14/18, 03/13/19, 12/11/19, 03/11/20, 01/13/21, 11/15/21, 12/08/21, 05/11/22, 11/09/22, 03/08/23, 05/10/23, 11/08/23, 11/13/24	
<b>PRIMARY BUSINESS OWNER:</b> UM		<b>COMMITTEE/BOARD APPROVAL</b> Evolut Specialty Services Clinical Guideline Review Committee		
<b>NCQA STANDARDS</b> UM 2		<b>ADDITIONAL AREAS OF IMPACT</b>		
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid	

### I. PURPOSE

To define and describe the accepted indications for Inlyta (axitinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolut is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolut may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

### II. INDICATIONS FOR USE/INCLUSION CRITERIA

#### A. Continuation requests for a not-approvable medication shall be exempt from this Evolut policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

#### B. Renal Cell Carcinoma (RCC)

1. Inlyta (axitinib) may be used in combination with Keytruda (pembrolizumab) as first line treatment for recurrent or metastatic, IMDC favorable risk renal cell carcinoma.

<b>IMDC CRITERIA = Assign 1 point for each</b>	<b>RISK CATEGORIES = RISK SCORE</b>
Time to systemic treatment less than 1 year from diagnosis	Favorable Risk = 0
Performance Status <80% Karnofsky Scale	Intermediate Risk = 1-2
Hemoglobin < LLN; 12 g/dL	Poor Risk = 3-6
Calcium > ULN; >12 mg/dL	
Neutrophils > ULN	
Platelets > ULN	

2. NOTE: The use of Inlyta (axitinib) in RCC is not supported by Evolent Policy when used as follows:

- a. First line, favorable/intermediate/poor risk clear cell RCC: single agent Inlyta (axitinib)
- b. Subsequent line clear cell RCC: Inlyta (axitinib) + Bavencio (avelumab).

The above policy position is based on the lack of Level 1 Evidence (randomized clinical trials and/or meta-analyses) to show superior outcomes compared to Evolent recommended alternatives agents/regimens, including but not limited to regimens at

<http://pathways.newcenturyhealth.com>.

### III. EXCLUSION CRITERIA

- A. Member has disease progression while taking Inlyta (axitinib).
- B. Dosing exceeds single dose limit of Inlyta (axitinib) 10 mg.
- C. Treatment with Inlyta (axitinib) exceeds the maximum limit of 180 (1 mg) tablets or 120 (5 mg) tablets a month.
- D. Investigational use of Inlyta (axitinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
  6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
  7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

## IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

## V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

## VI. ATTACHMENTS

- A. None

## VII. REFERENCES

- A. Sternberg CN, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. *Eur J Cancer*. 2013 Apr;49(6):1287-96.
- B. Motzer RJ, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. *N Engl J Med*. 2014 May 1;370(18):1769-70.
- C. Buti, Sebastiano, et al. First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study. *J Clin Oncol* 34, 2016 (suppl; abstr e16081).
- D. Choueiri TK, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1814-23.
- E. Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2018 Apr 5;378(14):1277-1290.
- F. Inlyta prescribing information. Pfizer Inc. New York, NY 2024.
- G. Clinical Pharmacology Elsevier Gold Standard 2024.
- H. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2024.
- I. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2024.
- J. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2024.
- K. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
- L. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.